Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 2.39B +279.1% |
| Revenue (ttm) | 36.77M -58.4% |
| Net Income | -341.35M |
| EPS | -3.41 |
| Shares Out | 103.78M |
| PE Ratio | n/a |
| Forward PE | 5.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,540,070 |
| Open | 23.78 |
| Previous Close | 23.65 |
| Day's Range | 22.98 - 23.81 |
| 52-Week Range | 8.22 - 28.23 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 33.93 (+47.46%) |
| Est. Earnings | Oct 8, 2026 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical tr... [Read more]
Financial Performance
In fiscal year 2025, Nurix Therapeutics's revenue was $83.98 million, an increase of 53.95% compared to the previous year's $54.55 million. Losses were -$264.46 million, 36.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price target is $33.93, which is an increase of 47.46% from the latest price.
News
Nurix Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A landmark Roche partnership accelerates clinical and commercial plans for bexobrutideg in oncology and immunology, with major trials underway in CLL, NHL, CSU, and MS. Additional partnered programs with Sanofi and Gilead advance in STAT6 and IRAK4, supporting a robust, milestone-rich pipeline.
Nurix Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A landmark Roche partnership expands the clinical and commercial reach of a BTK degrader, with pivotal trials underway and a strong safety profile supporting broad development in oncology and autoimmune diseases. Additional partnered programs and novel DAC technology further enhance future growth prospects.
Nurix Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
The discussion highlighted robust clinical progress for the BTK degrader in CLL, CSU, and MS, a landmark $700M+ partnership with Roche, and a diversified pipeline with multiple collaborations. Key updates are expected in pivotal CLL trials, CSU/MS phase I data, and new preclinical assets.
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients w...
Nurix earns $10M milestone from Sanofi on STAT6 degrader Phase 1 start
Nurix Therapeutics (NRIX) announced that it has earned a $10M milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911,...
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to ...
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor Phase 3 trial desig...
Nurix Therapeutics price target raised to $38 from $36 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Nurix Therapeutics (NRIX) to $38 from $36 and keeps an Overweight rating on the shares. The firm updated its model for the…
Nurix Therapeutics price target raised to $31 from $23 at UBS
UBS raised the firm’s price target on Nurix Therapeutics (NRIX) to $31 from $23 and keeps a Buy rating on the shares. Multiple updates from autoimmune programs are expected to…
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of t...
Nurix Therapeutics price target raised to $34 from $30 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $30 and keeps an Outperform rating on the shares. The firm believes bexdeg is…
Nurix Therapeutics price target raised to $34 from $32 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $32 and keeps a Buy rating on the shares after its Q2 results. The…
Nurix Therapeutics price target raised to $33 from $30 at RBC Capital
RBC Capital raised the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $30 and keeps an Outperform rating on the shares after its Q2 results. Coming off the…
Nurix Therapeutics price target raised to $40 from $34 at Stifel
Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $40 from $34 and keeps a Buy rating on the shares. The firm’s model has been adjusted reflect the…
Nurix Therapeutics price target raised to $34 from $32 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $32 and keeps a Buy rating on the shares after Q2 financial results were reported. The…
Nurix Therapeutics reports Q2 EPS (81c), consensus (72c)
Reports Q2 revenue $9.04M, consensus $15.29M. “The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field,” said Arthur Sands, president and chief executive…
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Nurix Therapeutics Earnings release: Q2 2026
Nurix Therapeutics released its Q2 2026 earnings on July 9, 2026, summarizing the period's financial results.
Nurix Therapeutics Quarterly report: Q2 2026
Nurix Therapeutics has published its Q2 2026 quarterly earnings report on July 9, 2026.
Nurix Therapeutics assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Nurix Therapeutics (NRIX) with an Outperform rating and $28 price target The firm likes the Nurix setup that mainly includes two very promising programs, namely Bexdeg…
Nurix Therapeutics price target raised to $33 from $26 at Baird
Baird raised the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $26 and keeps an Outperform rating on the shares. The firm raised its target to refelct is…
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median prog...
Nurix Therapeutics price target raised to $32 from $30 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $30 and keeps a Buy rating on the shares. The company’s disclosed partnership with…
Nurix Therapeutics price target raised to $32 from $30 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $30 and keeps a Buy rating on the shares. The firm notes that the…